https://www.alvotech.com/ 1 https://www.alvotech.com/is 1 https://www.alvotech.com/newsroom 0.8 https://www.alvotech.com/is/newsroom 0.8 https://www.alvotech.com/board-of-directors 2026-08-07T12:12:35.000Z 0.7 https://www.alvotech.com/is/stjorn 2026-08-07T12:12:35.000Z 0.7 https://www.alvotech.com/leadership 2026-08-07T12:11:41.000Z 0.7 https://www.alvotech.com/is/leadership 2026-08-07T12:11:41.000Z 0.7 https://www.alvotech.com/public-company-filings 2026-08-07T10:47:00.000Z 0.7 https://www.alvotech.com/committee-composition 2026-08-06T14:17:11.000Z 0.7 https://www.alvotech.com/is/committee-composition 2026-08-06T14:17:11.000Z 0.7 https://www.alvotech.com/events 2026-07-14T15:09:49.000Z 0.7 https://www.alvotech.com/is/vidburdir 2026-07-14T15:09:49.000Z 0.7 https://www.alvotech.com/earnings-calendar 2026-07-10T14:50:51.000Z 0.7 https://www.alvotech.com/is/earnings-calendar 2026-07-10T14:50:51.000Z 0.7 https://www.alvotech.com/careers 2026-07-10T14:21:49.000Z 0.7 https://www.alvotech.com/is/storf 2026-07-10T14:21:49.000Z 0.7 https://www.alvotech.com/guidelines-for-alvotech-applicants 2026-07-10T14:15:27.000Z 0.7 https://www.alvotech.com/is/leidbeiningar-fyrir-umsaekjendur 2026-07-10T14:15:27.000Z 0.7 https://www.alvotech.com/governance 2026-07-09T13:03:32.000Z 0.7 https://www.alvotech.com/is/stjornarhaettir 2026-07-09T13:03:32.000Z 0.7 https://www.alvotech.com/investors-governance 2026-07-09T12:33:06.000Z 0.7 https://www.alvotech.com/is/fjarfestar-stjornarhaettir 2026-07-09T12:33:06.000Z 0.7 https://www.alvotech.com/robert-wessman 2026-07-09T12:17:16.000Z 0.7 https://www.alvotech.com/is/robert-wessman 2026-07-09T12:17:16.000Z 0.7 https://www.alvotech.com/biosimilars-and-sustainability 2026-07-08T16:00:37.000Z 0.7 https://www.alvotech.com/is/biosimilars-and-sustainability 2026-07-08T16:00:37.000Z 0.7 https://www.alvotech.com/social 2026-07-08T15:58:37.000Z 0.7 https://www.alvotech.com/is/social 2026-07-08T15:58:37.000Z 0.7 https://www.alvotech.com/culture-and-values 2026-07-08T15:57:34.000Z 0.7 https://www.alvotech.com/is/menning 2026-07-08T15:57:34.000Z 0.7 https://www.alvotech.com/fun-facts-to-know 2026-07-08T15:56:31.000Z 0.7 https://www.alvotech.com/healthcare-in-iceland 2026-07-08T15:55:19.000Z 0.7 https://www.alvotech.com/pension-system 2026-07-08T15:54:30.000Z 0.7 https://www.alvotech.com/day-care-and-schooling 2026-07-08T15:53:56.000Z 0.7 https://www.alvotech.com/peace-and-security 2026-07-08T15:53:05.000Z 0.7 https://www.alvotech.com/reykjavik-and-the-surrounding-area 2026-07-08T15:51:46.000Z 0.7 https://www.alvotech.com/natural-beauty-of-iceland-environment 2026-07-08T15:50:30.000Z 0.7 https://www.alvotech.com/convenient-location 2026-07-08T15:49:57.000Z 0.7 https://www.alvotech.com/language 2026-07-08T15:49:19.000Z 0.7 https://www.alvotech.com/media-center 2026-07-08T15:48:34.000Z 0.7 https://www.alvotech.com/is/media-center 2026-07-08T15:48:34.000Z 0.7 https://www.alvotech.com/social-life 2026-07-08T15:46:20.000Z 0.7 https://www.alvotech.com/contact-us 2026-07-08T15:45:39.000Z 0.7 https://www.alvotech.com/is/hafa-samband 2026-07-08T15:45:39.000Z 0.7 https://www.alvotech.com/stock-quote 2026-07-08T15:44:23.000Z 0.7 https://www.alvotech.com/is/stock-quote 2026-07-08T15:44:23.000Z 0.7 https://www.alvotech.com/privacy-policy 2026-07-08T15:42:10.000Z 0.7 https://www.alvotech.com/employment-process-in-iceland 2026-07-08T15:40:36.000Z 0.7 https://www.alvotech.com/facilities 2026-07-08T15:38:30.000Z 0.7 https://www.alvotech.com/sec-filings 2026-07-07T17:18:58.000Z 0.7 https://www.alvotech.com/is/sec-filings 2026-07-07T17:18:58.000Z 0.7 https://www.alvotech.com/housing 2026-07-07T15:48:05.000Z 0.7 https://www.alvotech.com/locations 2026-07-07T15:46:47.000Z 0.7 https://www.alvotech.com/is/starfsstodvar 2026-07-07T15:46:47.000Z 0.7 https://www.alvotech.com/partnerships 2026-07-07T15:45:33.000Z 0.7 https://www.alvotech.com/is/samstarf 2026-07-07T15:45:33.000Z 0.7 https://www.alvotech.com/our-approach 2026-07-07T15:44:15.000Z 0.7 https://www.alvotech.com/is/okkar-nalgun 2026-07-07T15:44:15.000Z 0.7 https://www.alvotech.com/about-us 2026-07-07T15:42:35.000Z 0.7 https://www.alvotech.com/is/about-us 2026-07-07T15:42:35.000Z 0.7 https://www.alvotech.com/environment 2026-07-07T15:41:38.000Z 0.7 https://www.alvotech.com/is/umhverfi 2026-07-07T15:41:38.000Z 0.7 https://www.alvotech.com/shareholders 2026-07-07T15:39:06.000Z 0.7 https://www.alvotech.com/is/hluthafar 2026-07-07T15:39:06.000Z 0.7 https://www.alvotech.com/investor-contacts 2026-07-07T15:37:23.000Z 0.7 https://www.alvotech.com/is/fjarfestatengsl 2026-07-07T15:37:23.000Z 0.7 https://www.alvotech.com/pipeline 2026-07-07T15:32:51.000Z 0.7 https://www.alvotech.com/is/pipeline 2026-07-07T15:32:51.000Z 0.7 https://www.alvotech.com/financials 2026-07-07T15:30:16.000Z 0.7 https://www.alvotech.com/is/financials 2026-07-07T15:30:16.000Z 0.7 https://www.alvotech.com/us-resident-verification 2026-07-07T15:30:07.000Z 0.7 https://www.alvotech.com/documents-charters 2026-07-02T12:21:04.000Z 0.7 https://www.alvotech.com/annual-general-meeting 2026-06-04T13:33:16.000Z 0.7 https://www.alvotech.com/is/annual-general-meeting 2026-06-04T13:33:16.000Z 0.7 https://www.alvotech.com/faq 2026-05-26T17:24:50.000Z 0.7 https://www.alvotech.com/is/faq 2026-05-26T17:24:50.000Z 0.7 https://www.alvotech.com/corporate-sustainability 2026-05-21T16:11:16.000Z 0.7 https://www.alvotech.com/is/corporate-sustainability 2026-05-21T16:11:16.000Z 0.7 https://www.alvotech.com/letter-from-chairman 2026-05-21T16:07:20.000Z 0.7 https://www.alvotech.com/analyst-coverage 2026-05-21T15:19:28.000Z 0.7 https://www.alvotech.com/is/analyst-coverage 2026-05-21T15:19:28.000Z 0.7 https://www.alvotech.com/unsubscribe 2026-05-07T13:39:48.000Z 0.7 https://www.alvotech.com/is/unsubscribe 2026-05-07T13:39:48.000Z 0.7 https://www.alvotech.com/test-page 2025-12-04T12:14:00.000Z 0.7 https://www.alvotech.com/moving-to-iceland 2025-12-03T11:10:51.000Z 0.7 https://www.alvotech.com/contact-us-success 2025-11-30T22:17:43.000Z 0.7 https://www.alvotech.com/cookie-policy 2025-11-30T20:27:24.000Z 0.7 https://www.alvotech.com/foreign-tax-exemption 2025-11-28T15:08:51.000Z 0.7 https://www.alvotech.com/un-global-compact 2025-11-26T15:57:25.000Z 0.7 https://www.alvotech.com/reporting-guidelines 2025-11-26T15:54:24.000Z 0.7 https://www.alvotech.com/confirmation 2025-11-21T19:32:15.000Z 0.7 https://www.alvotech.com/terms-of-use 2025-11-13T18:46:04.000Z 0.7 https://www.alvotech.com/people/lisa-graver 2026-08-04T15:30:09.000Z 0.5 https://www.alvotech.com/is/people/lisa-graver 2026-08-04T15:30:09.000Z 0.5 https://www.alvotech.com/people/hjorleifur-palsson 2026-08-04T15:28:10.000Z 0.5 https://www.alvotech.com/is/people/hjorleifur-palsson 2026-08-04T15:28:10.000Z 0.5 https://www.alvotech.com/people/arni-hardarson 2026-08-04T15:20:28.000Z 0.5 https://www.alvotech.com/is/people/arni-hardarson 2026-08-04T15:20:28.000Z 0.5 https://www.alvotech.com/people/ann-merchant 2026-08-04T15:16:40.000Z 0.5 https://www.alvotech.com/is/people/ann-merchant 2026-08-04T15:16:40.000Z 0.5 https://www.alvotech.com/people/tomas-ekman 2026-08-04T15:11:48.000Z 0.5 https://www.alvotech.com/is/people/tomas-ekman 2026-08-04T15:11:48.000Z 0.5 https://www.alvotech.com/people/richard-davies 2026-08-04T15:06:24.000Z 0.5 https://www.alvotech.com/is/people/richard-davies 2026-08-04T15:06:24.000Z 0.5 https://www.alvotech.com/people/joseph-e-mcclellan 2026-08-04T14:56:28.000Z 0.5 https://www.alvotech.com/is/people/joseph-e-mcclellan 2026-08-04T14:56:28.000Z 0.5 https://www.alvotech.com/people/robert-wessman-chairman 2026-07-14T10:25:48.000Z 0.5 https://www.alvotech.com/is/people/robert-wessman-stjorn 2026-07-14T10:25:48.000Z 0.5 https://www.alvotech.com/people/neha-patel 2026-04-15T11:50:42.000Z 0.5 https://www.alvotech.com/is/people/neha-patel 2026-04-15T11:50:42.000Z 0.5 https://www.alvotech.com/people/robert-wessman-ceo 2026-03-02T12:33:48.000Z 0.5 https://www.alvotech.com/is/people/robert-wessman 2026-03-02T12:33:48.000Z 0.5 https://www.alvotech.com/people/kathryn-gunnarsson 2026-03-02T12:25:40.000Z 0.5 https://www.alvotech.com/is/people/kathryn-gunnarsson 2026-03-02T12:25:40.000Z 0.5 https://www.alvotech.com/people/anthony-m-maffia-iii 2026-03-02T12:24:48.000Z 0.5 https://www.alvotech.com/is/people/anthony-m-maffia-iii 2026-03-02T12:24:48.000Z 0.5 https://www.alvotech.com/people/dr-balaji-prasad-md 2026-03-02T12:23:07.000Z 0.5 https://www.alvotech.com/is/people/dr-balaji-prasad-md 2026-03-02T12:23:07.000Z 0.5 https://www.alvotech.com/people/tanya-zharov 2026-03-02T12:22:37.000Z 0.5 https://www.alvotech.com/is/people/tanya-zharov 2026-03-02T12:22:37.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-successful-closure-of-fda-inspection-of-manufacturing-facility 2026-07-29T13:35:37.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tilkynnir-ad-matvaela-og-lyfjaeftirlit-bandarikjanna-fda-hefur-lokid-uttekt-sinni-a-framleidsluadstodu-felagsins 2026-07-29T13:35:37.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-26 2026-07-08T16:03:33.000Z 0.5 https://www.alvotech.com/is/newsroom/vidskipti-stjornenda-og-tengdra-adila-26 2026-07-08T16:03:33.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-further-strengthens-liquidity-by-securing-term-loan-facility-of-75-million 2026-07-01T08:05:11.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-styrkir-lausafjarstodu-sina-enn-frekar-med-adgengi-ad-75-milljona-dala-lansfjarmognun 2026-07-01T08:05:11.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-25 2026-07-08T16:03:40.000Z 0.5 https://www.alvotech.com/is/newsroom/vidskipti-stjornenda-og-tengdra-adila-25 2026-07-08T16:03:40.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-closing-of-public-offering-and-full-exercise-by-underwriters-of-option-to-purchase-additional-shares-raising-an-aggregate-of-165-million-with-concurrent-private- 2026-06-18T08:05:42.000Z 0.5 https://www.alvotech.com/is/newsroom/hlutafjarutbodi-alvotech-i-bandarikjunum-lokid-og-umsjonaradilar-nyttu-ser-ad-fullu-kauprett-a-vidbotarbrefum-svo-heildarandvirdi-ad-medtoldum-hlutum-keyptum-af-evropskum-fagfjarfe 2026-06-18T08:05:42.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-pricing-of-152-million-public-offering-of-ordinary-shares-and-concurrent-private-placement 2026-06-16T03:55:42.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tilkynnir-um-verd-og-uthlutun-hlutabrefa-ad-andvirdi-um-152-milljonir-dollara-i-utbodi-i-bandarikjunum-og-lokudu-utbodi-til-fagfjarfesta-a-evropska-efnahagssvaedinu 2026-06-16T03:55:42.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-proposed-125-million-public-offering-and-concurrent-private-placement-of-ordinary-shares 2026-06-15T20:05:36.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-efnir-til-utbods-a-hlutabrefum-i-bandarikjunum-ad-andvirdi-125-milljonir-dollara-samhlida-lokudu-utbodi-til-fagfjarfesta-a-evropska-efnahagssvaedinu 2026-06-15T20:05:36.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-1 2026-07-08T16:02:44.000Z 0.5 https://www.alvotech.com/is/newsroom/vidskipti-stjornenda-og-tengdra-adila-1 2026-07-08T16:02:44.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-fda-acceptance-of-biologics-license-application-for-avt16-a-proposed-interchangeable-biosimilar-to-entyvio 2026-06-08T08:05:26.000Z 0.5 https://www.alvotech.com/is/newsroom/matvaela-og-lyfjastofnun-bandarikjanna-tekur-til-afgreidslu-umsokn-alvotech-um-markadsleyfi-fyrir-avt16-fyrirhugada-hlidstaedu-vid-entyvio 2026-06-08T08:05:26.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-resubmission-of-u-s-biologics-license-applications-for-avt05-a-proposed-biosimilar-to-simponi-and-simponi-aria-and-avt06-a-proposed-biosimilar-to-eylea 2026-06-04T08:01:21.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-leggur-inn-ad-nyju-umsoknir-um-markadsleyfi-i-bandarikjunum-fyrir-hlidstaedur-vid-simponi-simponi-aria-og-eylea 2026-06-04T08:01:21.000Z 0.5 https://www.alvotech.com/newsroom/main-results-of-2026-annual-and-extraordinary-general-meeting 2026-06-03T20:35:26.000Z 0.5 https://www.alvotech.com/is/newsroom/nidurstada-adalfundar-alvotech-arid-2026 2026-06-03T20:35:26.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-present-at-upcoming-investor-conferences-in-june 2026-06-02T20:35:26.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tekur-thatt-i-thremur-fjarfestaradstefnum-i-bandarikjunum-i-juni 2026-06-02T20:35:26.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-islandsbanki-renew-market-making-agreement-for-alvo-shares-trading-on-nasdaq-iceland 2026-06-01T08:35:45.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-islandsbanki-endurnyja-samning-um-vidskiptavakt-med-bref-felagsins-i-kauphollinni 2026-06-01T08:35:45.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-completion-of-fda-surveillance-inspection-at-reykjavik-facility 2026-05-11T08:35:53.000Z 0.5 https://www.alvotech.com/is/newsroom/matvaela-og-lyfjaeftirlit-bandarikjanna-lykur-uttekt-a-framleidsluadstodu-alvotech 2026-05-11T08:35:53.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-q1-2026-financial-results 2026-05-08T15:28:18.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-uppgjor-fyrsta-arsfjordungs-2026 2026-05-08T15:28:18.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-a-change-in-its-executive-team 2026-05-06T14:36:07.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tilkynnir-breytingu-i-framkvaemdastjorn 2026-05-06T14:36:07.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-report-financial-results-for-the-first-quarter-of-2026 2026-04-29T13:47:45.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-uppgjor-fyrsta-arsfjordungs-2026-thann-6-mai-nk 2026-04-29T13:47:45.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-24 2026-07-13T13:43:48.000Z 0.5 https://www.alvotech.com/is/newsroom/vidskipti-stjornenda-og-tengdra-adila-32 2026-07-13T13:43:48.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-23 2026-07-13T13:42:37.000Z 0.5 https://www.alvotech.com/is/newsroom/vidskipti-stjornenda-og-tengdra-adila-31 2026-07-13T13:42:37.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-files-annual-report-with-the-sec 2026-04-29T13:27:57.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-arsreikning-a-eydubladi-20-f 2026-04-29T13:27:57.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-publishes-2025-annual-report 2026-04-29T13:27:58.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-arsskyrslu-fyrir-arid-2025 2026-04-29T13:27:58.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-q4-2025-and-full-year-2025-financial-results 2026-04-29T13:27:58.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-uppgjor-arsins-2025-og-fjorda-arsfjordungs 2026-04-29T13:27:58.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-report-fourth-quarter-and-full-year-2025-financial-results 2026-04-29T13:49:43.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-kynnir-uppgjor-arsins-2025-thann-19-mars-nk 2026-04-29T13:49:43.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-18 2026-07-08T16:03:53.000Z 0.5 https://www.alvotech.com/is/newsroom/vidskipti-stjornenda-og-tengdra-adila-18 2026-07-08T16:03:53.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-increase-in-number-of-own-shares-22 2026-06-15T20:30:06.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tilkynnir-um-aukningu-i-fjolda-eigin-brefa 2026-06-15T20:30:06.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-positive-top-line-results-from-pivotal-pharmacokinetic-study-for-proposed-biosimilar-to-entyvio 2026-04-29T13:28:00.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-kynnir-jakvaeda-nidurstodu-rannsoknar-a-lyfjahvorfum-avt80-fyrirhugadrar-hlidstaedu-vid-liftaeknilyfid-entyvio 2026-04-29T13:28:00.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-enters-supply-and-commercialization-agreements-for-canada-and-australia-new-zealand-covering-multiple-biosimilar-candidates 2026-04-29T13:28:01.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-gerir-samninga-um-markadssetningu-a-fyrirhugudum-hlidstaedum-i-kanada-astraliu-og-nyja-sjalandi 2026-04-29T13:28:01.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-secures-settlement-agreement-in-global-markets-for-its-biosimilar-to-eylea-2mg 2026-04-29T13:28:01.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-naer-samningum-um-althjodlega-markadssetningu-hlidstaedu-vid-augnlyfid-eylea 2026-04-29T13:28:01.000Z 0.5 https://www.alvotech.com/newsroom/correction-transactions-of-managers-and-closely-associated-persons-21 2026-07-08T16:03:46.000Z 0.5 https://www.alvotech.com/is/newsroom/leidretting-vidskipti-stjornenda-og-tengdra-adila-21 2026-07-08T16:03:46.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-17 2026-07-08T16:03:59.000Z 0.5 https://www.alvotech.com/is/newsroom/vidskipti-stjornenda-og-tengdra-adila-17 2026-07-08T16:03:59.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-16 2026-07-08T16:03:26.000Z 0.5 https://www.alvotech.com/is/newsroom/vidskipti-stjornenda-og-tengdra-adila-16 2026-07-08T16:03:26.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-planned-ceo-succession-and-leadership-transition 2026-04-29T13:50:17.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tilkynnir-breytingar-a-yfirstjorn-felagsins 2026-04-29T13:50:17.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-secures-term-loan-facility-of-usd-100-million 2026-04-29T13:28:04.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tryggir-100-milljona-dollara-fjarmognun 2026-04-29T13:28:04.000Z 0.5 https://www.alvotech.com/newsroom/changes-in-company-s-own-shares 2026-04-29T13:28:04.000Z 0.5 https://www.alvotech.com/is/newsroom/breyting-a-fjolda-eigin-hluta 2026-04-29T13:28:04.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-s-financial-calendar-for-2026 2026-04-29T13:28:05.000Z 0.5 https://www.alvotech.com/is/newsroom/fjarhagsdagatal-alvotech-fyrir-arid-2026 2026-04-29T13:28:05.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-european-launch-of-first-in-market-biosimilar-to-simponi-golimumab-globally-by-partner-advanz-pharma 2026-04-29T13:50:43.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-advanz-pharma-hefja-solu-i-evropu-a-fyrstu-hlidstaedunni-vid-simponi 2026-04-29T13:50:43.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-teva-secure-u-s-settlement-date-for-avt06-a-proposed-biosimilar-to-eylea 2026-04-29T13:51:04.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-teva-na-samningi-um-ad-sala-avt06-hlidstaedunnar-vid-eylea-ma-hefjast-i-bandarikjunum-a-fjorda-arsfjordungi-2026 2026-04-29T13:51:04.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-successfully-places-usd-108-million-senior-unsecured-convertible-bonds-in-a-significantly-oversubscribed-offering 2026-04-29T13:28:06.000Z 0.5 https://www.alvotech.com/is/newsroom/mikil-umframeftirspurn-althjodlegra-fjarfesta-i-utbodi-alvotech-a-breytanlegra-skuldabrefum-ad-fjarhaed-108-milljonir-dollara 2026-04-29T13:28:06.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-launches-100-million-senior-unsecured-convertible-bond-offering-to-continue-strong-investment-in-r-d-support-manufacturing-global-product-launches-and-enhance-liquidity-po 2026-04-29T13:28:07.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-bydur-ut-breytanleg-skuldabref-ad-fjarhaed-100-milljonir-bandarikjadala-til-ad-vidhalda-fjarfestingu-i-lyfjathroun-framleidslu-markadssetningu-og-styrkja-lausafjarstodu-stad 2026-04-29T13:28:07.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-approval-of-avt03-a-biosimilar-to-prolia-and-xgeva-denosumab-in-the-european-economic-area 2026-04-29T13:28:07.000Z 0.5 https://www.alvotech.com/is/newsroom/markadsleyfi-veitt-a-evropska-efnahagssvaedinu-fyrir-avt03-hlidstaedu-alvotech-vid-liftaeknilyfin-prolia-og-xgeva 2026-04-29T13:28:07.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-advanz-pharma-receive-marketing-approval-across-the-european-economic-area-for-gobivaz-a-first-in-market-biosimilar-to-simponi-golimumab 2026-04-29T13:51:28.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-advanz-pharma-fa-markadsleyfi-a-evropska-efnahagssvaedinu-fyrir-gobivaz-fyrstu-hlidstaeduna-vid-simponi 2026-04-29T13:51:28.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-reports-results-for-the-first-nine-months-of-2025-and-provides-a-business-update 2026-04-29T13:28:08.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-kynnir-uppgjor-fyrstu-niu-manada-arsins-2025-og-helstu-afanga-i-rekstri-felagsins 2026-04-29T13:28:08.000Z 0.5 https://www.alvotech.com/newsroom/uk-high-court-rules-in-favor-of-alvotech-paving-way-for-manufacture-and-market-entry-of-avt06-biosimilar-to-eylea-aflibercept 2026-04-29T13:51:55.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-vinnur-sigur-i-mikilvaegu-domsmali-um-framleidslu-og-markadssetningu-avt06-hlidstaedunnar-vid-eylea-aflibercept 2026-04-29T13:51:55.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-advanz-pharma-receive-marketing-authorisations-for-gobivaz-a-biosimilar-to-simponi-golimumab-from-the-mhra 2026-04-29T13:28:09.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-advanz-pharma-fa-markadsleyfi-i-bretlandi-fyrir-gobivaz-hlidstaedu-vid-simponi-golimumab 2026-04-29T13:28:09.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-webcast-on-november-13-2025-to-report-financial-results-for-the-first-nine-months-of-2025-and-provide-a-business-update 2026-04-29T13:53:56.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-kynnir-afkomu-fyrstu-niu-manada-arsins-og-raedir-nyjustu-afanga-i-rekstri-felagsins-thann-13-november-nk 2026-04-29T13:53:56.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-provides-update-on-the-status-of-u-s-biologics-license-application-for-avt05 2026-06-15T19:56:16.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-nyjar-upplysingar-um-stodu-umsoknar-um-markadsleyfi-fyrir-avt05-i-bandarikjunum 2026-06-15T19:56:16.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-changes-in-global-business-development-and-commercial-operations-team 2026-04-29T13:54:34.000Z 0.5 https://www.alvotech.com/is/newsroom/skipulagsbreytingar-a-vidskiptasvidi-alvotech 2026-04-29T13:54:34.000Z 0.5 https://www.alvotech.com/newsroom/european-marketing-application-for-avt23-a-proposed-biosimilar-to-xolair-omalizumab-accepted-by-the-european-medicines-agency 2026-04-29T13:28:11.000Z 0.5 https://www.alvotech.com/is/newsroom/lyfjastofnun-evropu-tekur-til-umsagnar-umsokn-um-markadsleyfi-fyrir-fyrirhugada-hlidstaedu-alvotech-vid-liftaeknilyfid-xolair 2026-04-29T13:28:11.000Z 0.5 https://www.alvotech.com/newsroom/european-medicines-agency-recommends-marketing-authorization-of-avt03-alvotech-s-proposed-biosimilar-to-prolia-and-xgeva 2026-04-29T13:28:11.000Z 0.5 https://www.alvotech.com/is/newsroom/evropska-lyfjastofnunin-maelir-med-utgafu-markadsleyfis-fyrir-avt03-fyrirhugada-hlidstaedu-alvotech-vid-liftaeknilyfin-prolia-og-xgeva 2026-04-29T13:28:11.000Z 0.5 https://www.alvotech.com/newsroom/european-medicines-agency-recommends-marketing-approval-of-gobivaz-alvotech-s-proposed-biosimilar-to-simponi-golimumab-with-advanz-pharma-as-commercialization-partner 2026-04-29T13:28:12.000Z 0.5 https://www.alvotech.com/is/newsroom/lyfjastofnun-evropu-maelir-med-leyfi-til-markadssetningar-a-gobivaz-fyrirhugadri-hlidstaedu-alvotech-vid-liftaeknilyfid-simponi-golimumab 2026-04-29T13:28:12.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-marketing-approval-in-japan-of-three-new-biosimilars 2026-04-29T13:28:12.000Z 0.5 https://www.alvotech.com/is/newsroom/markadsleyfi-veitt-i-japan-fyrir-thrjar-nyjar-liftaeknilyfjahlidstaedur-fra-alvotech 2026-04-29T13:28:12.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-meets-investors-and-participates-in-a-fireside-chat-at-the-morgan-stanley-23rd-annual-global-healthcare-conference-in-new-york 2026-04-29T13:54:59.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tekur-thatt-i-23-arlegu-heilbrigdisradstefnu-fjarfestingabankans-morgan-stanley-i-new-york 2026-04-29T13:54:59.000Z 0.5 https://www.alvotech.com/newsroom/advanz-pharma-and-alvotech-receive-european-approval-for-mynzepli-biosimilar-to-eylea 2026-04-29T13:55:34.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-hlytur-leyfi-til-markadssetningar-i-evropu-a-hlidstaedu-vid-augnlyfid-eylea 2026-04-29T13:55:34.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-appoints-patrik-ling-as-vp-of-investor-relations-scandinavia 2026-07-09T09:52:00.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-reports-results-for-the-first-six-months-of-2025-and-provides-a-business-update 2026-04-29T13:56:18.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-uppgjor-fyrir-fyrstu-sex-manudi-arsins-og-kynnir-nyjustu-afanga-i-rekstri-felagsins 2026-04-29T13:56:18.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-webcast-to-report-financial-results-for-the-first-half-of-2025-on-august-14-2025-at-8-00-am-edt 2026-04-29T13:56:45.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-kynnir-uppgjor-fyrri-helmings-arsins-2025-thann-14-agust-nk-kl-12-a-hadegi 2026-04-29T13:56:45.000Z 0.5 https://www.alvotech.com/newsroom/information-filed-with-the-u-s-securities-and-exchange-commission 2026-07-09T13:05:46.000Z 0.5 https://www.alvotech.com/is/newsroom/skjol-logd-inn-til-verdbrefaeftirlits-bandarikjanna-sec 2026-07-09T13:05:46.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-appoints-linda-jonsdottir-as-chief-financial-officer 2026-04-29T13:57:03.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-skipar-lindu-jonsdottur-i-stodu-framkvaemdastjora-fjarmalasvids 2026-04-29T13:57:03.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-expands-its-capacity-in-assembly-and-packaging-with-the-acquisition-of-ivers-lee-group-in-switzerland 2026-04-29T13:28:16.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-kaupir-alla-starfsemi-ivers-lee-grou 2026-04-29T13:28:16.000Z 0.5 https://www.alvotech.com/newsroom/notification-for-the-purposes-of-article-13-of-the-luxembourg-law-of-11-january-2008-on-transparency-requirements-for-issuers 2026-07-09T09:52:01.000Z 0.5 https://www.alvotech.com/newsroom/granting-of-stock-options-and-vesting-of-restricted-share-units 2026-04-29T13:28:16.000Z 0.5 https://www.alvotech.com/is/newsroom/uthlutun-nyrra-kaupretta-og-afhending-aunninna-hlutabrefarettinda 2026-04-29T13:28:16.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-advanz-pharma-enter-into-european-supply-and-commercialization-agreement-for-biosimilar-candidate-to-cimzia-certolizumab-pegol 2026-04-29T13:28:16.000Z 0.5 https://www.alvotech.com/is/newsroom/advanz-pharma-semur-vid-alvotech-um-markadssetningu-i-evropu-a-hlidstaedu-vid-liftaeknilyfid-cimzia 2026-04-29T13:28:16.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-s-lenders-lower-interest-on-senior-secured-term-loan-facility 2026-04-29T13:58:05.000Z 0.5 https://www.alvotech.com/is/newsroom/lanveitendur-alvotech-laekka-vexti-a-langtimaskuldum-felagsins 2026-04-29T13:58:05.000Z 0.5 https://www.alvotech.com/newsroom/main-results-of-2025-annual-and-extraordinary-general-meeting 2026-04-29T13:28:17.000Z 0.5 https://www.alvotech.com/is/newsroom/nidurstada-adalfundar-alvotech-arid-2025 2026-04-29T13:28:17.000Z 0.5 https://www.alvotech.com/newsroom/positive-top-line-results-from-confirmatory-efficacy-study-for-proposed-biosimilar-to-xolair-omalizumab 2026-04-29T13:58:32.000Z 0.5 https://www.alvotech.com/is/newsroom/jakvaed-nidurstada-ur-kliniskri-rannsokn-fyrir-fyrirhugada-hlidstaedu-alvotech-vid-liftaeknilyfid-xolair 2026-04-29T13:58:32.000Z 0.5 https://www.alvotech.com/newsroom/european-medicines-agency-recommends-market-approval-of-avt06-alvotech-s-proposed-biosimilar-to-eylea-aflibercept 2026-04-29T13:58:52.000Z 0.5 https://www.alvotech.com/is/newsroom/lyfjastofnun-evropu-maelir-med-thvi-ad-veita-markadsleyfi-fyrir-avt06-fyrirhugada-hlidstaedu-alvotech-vid-augnlyfid-eylea 2026-04-29T13:58:52.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-s-private-placement-completed-with-delivery-of-sdrs-and-shares-to-investors 2026-04-29T13:59:32.000Z 0.5 https://www.alvotech.com/is/newsroom/oll-bref-afhent-kaupendum-i-hlutafjarutbodi-alvotech 2026-04-29T13:59:32.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-participates-in-the-goldman-sachs-global-healthcare-conference-in-miami 2026-04-29T13:28:19.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tekur-thatt-i-arlegri-heilbrigdisradstefnu-goldman-sachs-fjarfestingabankans-i-miami 2026-04-29T13:28:19.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-dr-reddy-s-enter-into-collaboration-to-co-develop-biosimilar-candidate-to-keytruda-pembrolizumab 2026-04-29T14:00:05.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-dr-reddys-ganga-til-samstarfs-um-throun-hlidstaedu-vid-krabbameinslyfid-keytruda 2026-04-29T14:00:05.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-has-carried-out-a-private-placement-of-7-500-000-sdrs-and-ordinary-shares-at-a-price-of-sek-100-00-per-sdr-and-isk-1320-83-per-ordinary-share-raising-gross-proceeds-of-sek 2026-04-29T13:28:20.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-lykur-lokudu-utbodi-a-alls-7-500-000-saenskum-heimildarskirteinum-sdr-og-hlutabrefum-a-genginu-100-saenskar-kronur-fyrir-hvert-sdr-og-1-320-83-islenskar-kronur-fyrir-hvern-h 2026-04-29T13:28:20.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-intends-to-carry-out-a-private-placement-of-approximately-7-5-million-sdrs-and-ordinary-shares 2026-04-29T13:28:20.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-radgerir-utbod-til-stofnanafjarfesta-a-um-7-5-milljonum-saenskra-heimildarskirteina-og-hlutabrefum 2026-04-29T13:28:20.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-completes-acquisition-of-xbrane-r-d-organization-and-biosimilar-candidate-to-cimzia 2026-04-29T13:28:21.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-lykur-vid-kaup-a-rannsoknaradstodu-xbrane-og-fyrirhugadri-hlidstaedu-vid-cimzia 2026-04-29T13:28:21.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-meets-investors-and-presents-at-the-jefferies-global-healthcare-conference-2025-in-new-york-ny 2026-04-29T14:00:28.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-fundar-med-fjarfestum-a-arlegri-heilbrigdisradstefnu-jefferies-fjarfestingabankans-i-new-york-og-flytur-kynningu 2026-04-29T14:00:28.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-advanz-pharma-extend-strategic-partnership-to-commercialize-three-additional-biosimilars-in-europe 2026-04-29T14:00:49.000Z 0.5 https://www.alvotech.com/is/newsroom/advanz-pharma-semur-vid-alvotech-um-rett-til-markadssetningar-thriggja-fyrirhugadra-hlidstaeda-til-vidbotar-i-evropu 2026-04-29T14:00:49.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-annual-general-meeting-to-be-held-june-25-2025 2026-04-29T13:28:22.000Z 0.5 https://www.alvotech.com/is/newsroom/adalfundur-alvotech-bodadur-25-juni-2025 2026-04-29T13:28:22.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-15 2026-07-08T16:03:19.000Z 0.5 https://www.alvotech.com/is/newsroom/vidskipti-stjornenda-og-tengdra-adila-15 2026-07-08T16:03:19.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-appoints-dnb-carnegie-as-liquidity-provider-on-nasdaq-stockholm 2026-04-29T13:28:23.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-semur-vid-fjarfestingabankann-dnb-carnegie-um-vidskiptavakt-a-nasdaq-markadnum-i-stokkholmi 2026-04-29T13:28:23.000Z 0.5 https://www.alvotech.com/newsroom/trading-in-alvotech-s-shares-on-nasdaq-stockholm-commences-today 2026-04-29T13:28:24.000Z 0.5 https://www.alvotech.com/is/newsroom/vidskipti-med-bref-i-alvotech-hefjast-a-nasdaq-markadnum-i-stokkholmi-i-dag 2026-04-29T13:28:24.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-the-outcome-of-the-offering-in-connection-with-the-company-s-listing-on-nasdaq-stockholm 2026-04-29T13:28:24.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tilkynnir-nidurstodu-utbods-i-tengslum-vid-skraningu-felagsins-a-nasdaq-markadinn-i-stokkholmi 2026-04-29T13:28:24.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-14 2026-07-08T16:03:10.000Z 0.5 https://www.alvotech.com/is/newsroom/vidskipti-stjornenda-og-tengdra-adila-14 2026-07-08T16:03:10.000Z 0.5 https://www.alvotech.com/is/newsroom/leidretting-vidskipti-stjornenda-og-tengdra-adila-22 2026-07-09T09:52:01.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-13 2026-07-08T16:03:02.000Z 0.5 https://www.alvotech.com/is/newsroom/vidskipti-stjornenda-og-tengdra-adila-13 2026-07-08T16:03:02.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-meets-investors-and-participates-in-fireside-chat-at-the-bofa-securities-healthcare-conference-2025-in-las-vegas-nevada 2026-04-29T14:01:28.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-fundar-med-fjarfestum-a-heilbrigdisradstefnu-bofa-securities-i-las-vegas-og-situr-fyrir-svorum 2026-04-29T14:01:28.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-12 2026-07-08T16:02:55.000Z 0.5 https://www.alvotech.com/is/newsroom/vidskipti-stjornenda-og-tengdra-adila-12 2026-07-08T16:02:55.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-publishes-prospectus-in-connection-with-its-listing-on-nasdaq-stockholm 2026-07-09T09:55:32.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-reports-results-for-the-first-quarter-of-2025-and-provides-business-update 2026-04-29T14:02:57.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-uppgjor-fyrir-fyrsta-arsfjordung-2025-og-kynnir-nyjustu-afanga-i-rekstri-felagsins 2026-04-29T14:02:57.000Z 0.5 https://www.alvotech.com/newsroom/potential-u-s-tariffs-on-pharmaceuticals-expected-to-have-minimal-impact-on-alvotech-s-product-revenues-in-2025 2026-04-29T13:28:33.000Z 0.5 https://www.alvotech.com/is/newsroom/mogulegir-tollar-a-innflutning-lyfja-til-bandarikjanna-hefdu-hverfandi-ahrif-a-tekjur-alvotech-a-arinu 2026-04-29T13:28:33.000Z 0.5 https://www.alvotech.com/newsroom/teva-and-alvotech-announce-fda-approval-of-interchangeability-for-selarsdi-ustekinumab-aekn-with-stelara-ustekinumab 2026-04-29T14:03:42.000Z 0.5 https://www.alvotech.com/is/newsroom/selarsdi-hlidstaedan-faer-fullan-utskiptileika-vid-frumlyfid-stelara-i-bandarikjunum 2026-04-29T14:03:42.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-webcast-of-first-quarter-2025-financial-results-on-may-8-2025-at-8-00-am-edt-14-00-cet 2026-04-29T13:28:34.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-kynnir-uppgjor-fyrsta-arsfjordungs-2025-8-mai-nk-kl-12-ad-islenskum-tima 2026-04-29T13:28:34.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-appoints-dr-balaji-v-prasad-as-chief-strategy-officer 2026-07-09T09:55:32.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-reports-record-results-for-2024-and-provides-business-update 2026-04-29T14:04:27.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-metuppgjor-fyrir-arid-2024-sem-synir-mikla-tekjuaukningu-og-kynnir-nyjar-aherslur-og-afanga-i-rekstri-felagsins 2026-04-29T14:04:27.000Z 0.5 https://www.alvotech.com/newsroom/uk-medicines-and-healthcare-products-regulatory-agency-confirms-acceptance-of-marketing-authorization-application-for-proposed-biosimilar-to-xolair-omalizumab 2026-04-29T14:04:49.000Z 0.5 https://www.alvotech.com/is/newsroom/lyfjastofnun-bretlands-samthykkir-ad-taka-til-umsagnar-umsokn-um-markadsleyfi-fyrir-fyrirhugada-hlidstaedu-vid-xolair 2026-04-29T14:04:49.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-acquires-xbrane-s-r-d-operations-in-sweden-and-further-affirms-its-global-leadership-position-in-biosimilars-development-and-production 2026-04-29T14:05:18.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-kaupir-throunarstarfsemi-liftaeknifyrirtaekisins-xbrane-i-svithjod 2026-04-29T14:05:18.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-dr-reddy-s-announce-fda-acceptance-of-biologic-license-application-for-avt03-a-proposed-biosimilar-to-prolia-and-xgeva 2026-04-29T13:28:35.000Z 0.5 https://www.alvotech.com/is/newsroom/matvaela-og-lyfjaeftirlit-bandarikjanna-fda-samthykkir-ad-taka-til-afgreidslu-umsokn-um-markadsleyfi-fyrir-avt03-fyrirhugada-hlidstaedu-vid-prolia-og-xgeva 2026-04-29T13:28:35.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-meeting-investors-and-participates-in-fireside-chat-at-barclays-27th-global-healthcare-conference-in-miami-florida 2026-04-29T13:28:36.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-fundar-med-fjarfestum-a-althjoda-heilbrigdisradstefnu-barclays-fjarfestingabankans-i-miami-og-situr-fyrir-svorum 2026-04-29T13:28:36.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-report-full-year-financial-results-for-2024-on-march-26-2025-and-hosts-conference-call-on-march-27-2025-at-8-00-am-et 2026-04-29T13:28:36.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-heldur-kynningarfund-fyrir-fjarfesta-27-mars-2025-eftir-birtingu-uppgjors-fyrir-arid-2024-og-fjorda-arsfjordung 2026-04-29T13:28:36.000Z 0.5 https://www.alvotech.com/newsroom/teva-and-alvotech-announce-selarsdi-ustekinumab-aekn-injection-now-available-in-the-u-s 2026-04-29T14:05:48.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-teva-tilkynna-ad-sala-er-hafin-i-bandarikjunum-a-selarsdi-ustekinumab-aekn-hlidstaedu-vid-liftaeknilyfid-stelara 2026-04-29T14:05:48.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-teva-announce-filing-acceptance-of-u-s-biologics-license-application-for-avt06-a-proposed-biosimilar-to-eylea-aflibercept 2026-04-29T14:06:15.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-teva-tilkynna-ad-umsokn-um-markadsleyfi-i-bandarikjunum-fyrir-avt06-fyrirhugada-hlidstaedu-vid-augnlyfid-eylea-hafi-verid-tekin-til-umsagnar 2026-04-29T14:06:15.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-teva-announce-filing-acceptance-of-u-s-biologics-license-applications-for-avt05-a-proposed-biosimilar-to-simponi-and-simponi-aria-golimumab 2026-04-29T13:28:37.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-teva-tilkynna-ad-fda-hefur-tekid-til-umsagnar-umsokn-um-markadsleyfi-i-bandarikjunum-fyrir-avt05-fyrirhugada-hlidstaedu-vid-simponi-og-simponi-aria-golimumab 2026-04-29T13:28:37.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons 2026-07-13T13:49:08.000Z 0.5 https://www.alvotech.com/is/newsroom/vidskipti-stjornenda-og-tengdra-adila-23 2026-07-13T13:49:08.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-fjarhagsdagatal-fyrir-arid-2025 2026-07-09T09:52:01.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-11 2026-06-15T20:09:55.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-added-to-nasdaq-biotech-index-effective-monday-december-23-2024 2026-04-29T14:06:42.000Z 0.5 https://www.alvotech.com/is/newsroom/hlutabref-alvotech-tekin-inn-i-liftaeknivistolu-nasdaq 2026-04-29T14:06:42.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-10 2026-07-13T13:28:30.000Z 0.5 https://www.alvotech.com/is/newsroom/vidskipti-stjornenda-og-tengdra-adila-27 2026-07-13T13:28:30.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-reports-financial-results-for-the-first-nine-months-of-2024 2026-04-29T14:07:07.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-fjarhagsuppgjor-fyrir-fyrstu-niu-manudi-arsins-2024 2026-04-29T14:07:07.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-attending-citi-s-global-healthcare-conference-on-december-4-2024-and-evercore-s-healthconx-conference-on-december-5-2024 2026-04-29T13:28:39.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-fundar-med-fjarfestum-a-heilbrigdisradstefnum-citi-og-evercore-fjarfestingabankanna-dagana-4-og-5-desember-2024 2026-04-29T13:28:39.000Z 0.5 https://www.alvotech.com/newsroom/european-medicines-agency-confirms-acceptance-of-marketing-authorization-application-for-avt05-a-proposed-biosimilar-to-simponi-golimumab 2026-04-29T13:28:39.000Z 0.5 https://www.alvotech.com/is/newsroom/lyfjastofnun-evropu-tekur-til-umsagnar-umsokn-um-markadsleyfi-fyrir-avt05-fyrirhugada-liftaeknilyfjahlidstaedu-vid-simponi-golimumab 2026-04-29T13:28:39.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-report-financial-results-for-the-first-nine-months-of-2024-on-november-13-2024-and-host-conference-call-on-november-14-2024-at-8-00-am-et 2026-04-29T13:28:39.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-mun-birta-uppgjor-fyrstu-niu-manada-arsins-midvikudaginn-13-november-nk-og-streyma-uppgjorsfundi-fimmtudaginn-14-november-nk-kl-13-00-ad-islenskum-tima 2026-04-29T13:28:39.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-meeting-investors-and-presenting-at-the-jefferies-2024-london-healthcare-conference-on-november-19-20-2024 2026-04-29T14:07:29.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-fundar-med-fjarfestum-og-heldur-kynningu-a-heilbrigdisradstefnu-jefferies-i-london-19-20-november-2024 2026-04-29T14:07:29.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-teva-announce-u-s-fda-approval-of-additional-presentation-of-selarsdi-ustekinumab-aekn-expanding-its-label-to-include-further-indications-approved-for-reference-produc 2026-04-29T14:08:00.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-veitt-aukid-markadsleyfi-i-bandarikjunum-fyrir-selarsdi-ustekinumab-aekn-liftaeknilyfjahlidstaedu-vid-stelara-til-medferdar-sjukdoma-i-meltingarvegi 2026-04-29T14:08:00.000Z 0.5 https://www.alvotech.com/newsroom/european-medicines-agency-confirms-acceptance-of-marketing-application-for-avt03-a-proposed-biosimilar-to-prolia-and-xgeva 2026-04-29T13:28:40.000Z 0.5 https://www.alvotech.com/is/newsroom/evropska-lyfjastofnunin-samthykkir-ad-taka-til-afgreidslu-umsokn-um-markadsleyfi-fyrir-avt03-fyrirhugada-hlidstaedu-vid-prolia-og-xgeva 2026-04-29T13:28:40.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-initiates-confirmatory-patient-study-for-avt16-a-proposed-biosimilar-to-entyvio 2026-04-29T13:28:41.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-hefur-kliniska-rannsokn-a-avt16-fyrirhugadri-liftaeknilyfjahlidstaedu-vid-entyvio 2026-04-29T13:28:41.000Z 0.5 https://www.alvotech.com/newsroom/registration-statement-declared-effective 2026-07-09T13:05:50.000Z 0.5 https://www.alvotech.com/is/newsroom/gildistaka-skraningarlysingar-i-bandarikjunum 2026-07-09T13:05:50.000Z 0.5 https://www.alvotech.com/newsroom/filing-of-a-request-with-the-sec 2026-07-09T13:05:50.000Z 0.5 https://www.alvotech.com/is/newsroom/beidni-alvotech-til-verdbrefaeftirlits-bandarikjanna-um-gildistoku-skraningarlysingar 2026-07-09T13:05:50.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-participate-in-the-morgan-stanley-22nd-annual-global-healthcare-conference 2026-04-29T13:28:49.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tekur-thatt-i-arlegri-heilbrigdisradstefnu-fjarfestingabankans-morgans-stanley 2026-04-29T13:28:49.000Z 0.5 https://www.alvotech.com/newsroom/filing-of-a-preliminary-prospectus-with-the-sec 2026-07-09T13:05:50.000Z 0.5 https://www.alvotech.com/is/newsroom/birting-umsoknar-til-sec-med-drogum-ad-vidbot-vid-skraningarlysingu-alvotech-i-bandarikjunum 2026-07-09T13:05:50.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-reports-record-revenues-and-adjusted-ebitda-for-the-second-quarter-and-first-six-months-of-2024 2026-04-29T13:28:50.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-skilar-mettekjum-og-metframlegd-a-odrum-arsfjordungi-og-a-fyrri-helmingi-arsins 2026-04-29T13:28:50.000Z 0.5 https://www.alvotech.com/newsroom/european-medicines-agency-confirms-acceptance-of-marketing-application-for-avt06-a-proposed-biosimilar-to-eylea-aflibercept 2026-04-29T14:09:11.000Z 0.5 https://www.alvotech.com/is/newsroom/lyfjastofnun-evropu-tekur-til-umsagnar-umsokn-um-markadsleyfi-fyrir-avt06-fyrirhugada-liftaeknilyfjahlidstaedu-vid-eylea 2026-04-29T14:09:11.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-report-financial-results-for-the-first-half-of-2024-on-august-15-2024-and-host-conference-call-on-august-16-2024-at-8-00-am-et 2026-04-29T14:09:29.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-mun-birta-uppgjor-fyrri-arshelmings-2024-fimmtudaginn-15-agust-nk-og-streyma-uppgjorsfundi-fostudaginn-16-agust-nk-kl-12-00-ad-islenskum-tima 2026-04-29T14:09:29.000Z 0.5 https://www.alvotech.com/newsroom/stada-and-alvotech-launch-uzpruvo-the-first-approved-ustekinumab-biosimilar-to-stelara-across-europe 2026-04-29T13:28:51.000Z 0.5 https://www.alvotech.com/is/newsroom/stada-og-alvotech-hefja-solu-a-uzpruvo-fyrstu-liftaeknilyfjahlidstaedunni-vid-stelara-i-evropu 2026-04-29T13:28:51.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-closing-of-private-debt-financing 2026-04-29T14:12:14.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-lykur-vid-endurfjarmognun-skulda-med-laegri-fjarmagnskostnadi-og-lengri-lanstima 2026-04-29T14:12:14.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-9 2026-06-15T20:09:42.000Z 0.5 https://www.alvotech.com/newsroom/major-shareholder-announcement 2026-07-13T13:28:33.000Z 0.5 https://www.alvotech.com/is/newsroom/breytingar-a-verulegum-hlut-atkvaedisrettar 2026-07-13T13:28:33.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-positive-topline-results-from-confirmatory-patient-study-for-avt03-a-proposed-biosimilar-for-prolia-and-xgeva 2026-04-29T13:28:52.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-kynnir-jakvaeda-nidurstodu-virknirannsoknar-a-avt03-fyrirhugadri-liftaeknilyfjahlidstaedu-vid-prolia-og-xgeva 2026-04-29T13:28:52.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-issues-new-shares-to-holders-of-convertible-bonds 2026-04-29T14:12:56.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-gefur-ut-nyja-hluti-i-skiptum-fyrir-breytileg-skuldabref 2026-04-29T14:12:56.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-record-preliminary-results-for-revenues-and-ebitda-for-the-second-quarter-of-2024 2026-04-29T14:13:37.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-kynnir-aaetladar-mettekjur-og-ebitda-framlegd-a-odrum-arsfjordungi-2024 2026-04-29T14:13:37.000Z 0.5 https://www.alvotech.com/newsroom/text-of-request-filed-with-the-u-s-securities-and-exchange-commission 2026-07-09T13:05:50.000Z 0.5 https://www.alvotech.com/is/newsroom/beidni-logd-inn-til-verdbrefaeftirlits-bandarikjanna-um-afturkollun-skraningarlysingar 2026-07-09T13:05:50.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-8 2026-07-13T13:28:31.000Z 0.5 https://www.alvotech.com/is/newsroom/vidskipti-stjornenda-og-tengdra-adila-28 2026-07-13T13:28:31.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-receives-conversion-notices-for-majority-of-convertible-bonds 2026-04-29T13:28:53.000Z 0.5 https://www.alvotech.com/is/newsroom/eigendur-meirihluta-breytilegra-skuldabrefa-alvotech-nyta-rett-til-ad-breyta-yfir-i-hlutabref 2026-04-29T13:28:53.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-advanz-pharma-sign-commercialization-agreement-for-proposed-biosimilar-to-eylea-ld-hd-in-europe 2026-04-29T14:14:06.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-advanz-pharma-undirrita-samning-um-markadssetningu-i-evropu-a-fyrirhugadri-liftaeknilyfjahlidstaedu-vid-eylea 2026-04-29T14:14:06.000Z 0.5 https://www.alvotech.com/newsroom/filing-of-form-6-k-with-the-u-s-securities-and-exchange-commission 2026-07-09T13:05:50.000Z 0.5 https://www.alvotech.com/is/newsroom/skjol-birt-a-vef-verdbrefaeftirlits-bandarikjanna 2026-07-09T13:05:50.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-stada-add-to-strategic-alliance-through-denosumab-partnership 2026-04-29T14:14:37.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-stada-utvikka-samstarf-sitt-med-nyjum-samningi-um-avt03-fyrirhugada-hlidstaedu-vid-prolia-og-xgeva 2026-04-29T14:14:37.000Z 0.5 https://www.alvotech.com/newsroom/granting-of-stock-options-and-restricted-share-units 2026-07-09T13:05:49.000Z 0.5 https://www.alvotech.com/is/newsroom/uthlutun-kaupretta-og-hlutabrefarettinda 2026-07-09T13:05:49.000Z 0.5 https://www.alvotech.com/newsroom/main-results-of-annual-and-extraordinary-general-meeting 2026-07-09T13:05:46.000Z 0.5 https://www.alvotech.com/is/newsroom/nidurstada-adalfundar 2026-07-09T13:05:46.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-strategic-refinancing-agreement 2026-04-29T14:15:13.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-gengur-fra-samningi-vid-althjodlega-fjarfesta-um-endurfjarmognun-skulda 2026-04-29T14:15:13.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-participate-in-jefferies-healthcare-conference-in-new-york-june-5-6-2024 2026-04-29T14:15:39.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tekur-thatt-i-heilbrigdisradstefnu-fjarfestingabankans-jefferies-i-new-york-dagana-5-6-juni-2024 2026-04-29T14:15:39.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-7 2026-07-13T13:28:31.000Z 0.5 https://www.alvotech.com/is/newsroom/vidskipti-stjornenda-og-tengdra-adila-29 2026-07-13T13:28:31.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-reports-financial-results-for-first-quarter-of-2024-and-provides-a-business-update 2026-04-29T14:16:15.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-uppgjor-fyrir-fyrsta-arsfjordung-2024-og-kynnir-nyjustu-afanga-i-rekstri-felagsins 2026-04-29T14:16:15.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-dr-reddy-s-enter-into-collaboration-for-commercialization-of-avt03-denosumab-a-biosimilar-candidate-to-prolia-xgeva-in-the-u-s-europe-and-uk 2026-04-29T13:29:11.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-gengur-til-samstarfs-vid-dr-reddy-s-um-markadssetningu-avt03-fyrirhugadrar-hlidstaedu-vid-prolia-og-xgeva-i-bandarikjunum-og-evropu 2026-04-29T13:29:11.000Z 0.5 https://www.alvotech.com/newsroom/teva-and-alvotech-announce-simlandi-adalimumab-ryvk-injection-now-available-in-the-u-s 2026-04-29T13:29:12.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-teva-pharmaceuticals-hefja-solu-a-liftaeknilyfjahlidstaedunni-simlandi-i-bandarikjunum 2026-04-29T13:29:12.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-s-a-annual-general-meeting-to-be-held-june-7-2024 2026-04-29T13:29:12.000Z 0.5 https://www.alvotech.com/is/newsroom/adalfundur-alvotech-s-a-bodadur-7-juni-2024 2026-04-29T13:29:12.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-webcast-of-first-quarter-2024-financial-results-on-may-22-2024-at-8-00-am-edt-12-noon-gmt 2026-04-29T13:29:12.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-kynnir-uppgjor-fyrsta-arsfjordungs-2024-22-mai-nk-kl-12-ad-islenskum-tima 2026-04-29T13:29:12.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-participation-at-bofa-securities-healthcare-conference-2024 2026-04-29T13:29:13.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tekur-thatt-i-heilbrigdisradstefnu-bofa-securities-i-bandarikjunum 2026-04-29T13:29:13.000Z 0.5 https://www.alvotech.com/newsroom/u-s-commercialization-agreement-with-quallent-to-drive-patient-savings-with-first-high-concentration-citrate-free-interchangeable-biosimilar-to-humira-adalimumab 2026-04-29T13:29:13.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-semur-vid-quallent-pharmaceuticals-um-markadssetningu-a-hlidstaedu-vid-humira-i-bandarikjunum 2026-04-29T13:29:13.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-topline-results-from-a-confirmatory-clinical-study-for-avt05-a-proposed-biosimilar-for-simponi-golimumab 2026-04-29T14:16:43.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-kynnir-jakvaeda-nidurstodu-rannsoknar-a-sjuklingum-sem-synir-somu-klinisku-virkni-liftaeknilyfjahlidstaedunnar-avt05-og-simponi-golimumab 2026-04-29T14:16:43.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-signs-u-s-agreement-to-expand-access-for-newly-approved-high-concentration-interchangeable-biosimilar-to-humira-adalimumab 2026-04-29T13:29:14.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-gerir-solusamning-i-bandarikjunum-um-fyrstu-liftaeknilyfjahlidstaeduna-i-haum-styrk-med-utskiptanleika-vid-humira 2026-04-29T13:29:14.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-teva-announce-u-s-fda-approval-of-selarsdi-ustekinumab-aekn-biosimilar-to-stelara-ustekinumab 2026-04-29T14:17:07.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-hlytur-markadsleyfi-i-bandarikjunum-fyrir-selarsdi-ustekinumab-aekn-liftaeknilyfjahlidstaedu-vid-stelara 2026-04-29T14:17:07.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-hosts-audio-call-for-investors-at-8-15-am-edt-on-april-3-2024 2026-04-29T14:17:23.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-streymir-kynningu-fyrir-fjarfesta-3-april-2024-kl-12-15-ad-islenskum-tima 2026-04-29T14:17:23.000Z 0.5 https://www.alvotech.com/newsroom/transaction-of-managers-and-closely-associated-persons-21 2026-07-09T13:05:46.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-increase-in-number-of-own-shares 2026-04-29T14:18:06.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tilkynnir-um-utgafu-eigin-hlutabrefa 2026-04-29T14:18:06.000Z 0.5 https://www.alvotech.com/newsroom/transaction-of-managers-and-closely-associated-persons-20 2026-06-15T20:11:39.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-reports-financial-results-for-full-year-2023-and-provides-a-business-update 2026-04-29T13:29:21.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-uppgjor-fyrir-arid-2023-og-kynnir-nyjustu-afanga-i-rekstri-felagsins 2026-04-29T13:29:21.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-webcast-of-full-year-2023-financial-results-on-march-21-2024-at-8-00-am-et 2026-04-29T13:29:21.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-heldur-uppgjorsfund-fyrir-arid-2023-i-beinu-streymi-thann-21-mars-nk-kl-12-00-ad-islenskum-tima 2026-04-29T13:29:21.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-appoints-interim-chief-quality-officer 2026-04-29T14:18:29.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-skipar-nyjan-framkvaemdastjora-gaedamala 2026-04-29T14:18:29.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-accepts-offer-for-the-sale-of-shares-for-a-value-of-approximately-usd-166-million-at-a-purchase-price-of-usd-16-41-isk-2-250-per-share 2026-04-29T13:29:22.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-gengur-ad-tilbodi-um-solu-hlutabrefa-ad-fjarhaed-um-22-8-milljardar-krona-um-166-milljonir-dala-a-genginu-2-250-kronur-16-41-dalir-a-hlut 2026-04-29T13:29:22.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-teva-announce-u-s-approval-of-simlandi-adalimumab-ryvk-injection-the-first-interchangeable-high-concentration-citrate-free-biosimilar-to-humira 2026-04-29T13:29:22.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-hlytur-markadsleyfi-i-bandarikjunum-fyrir-simlandi-liftaeknilyfjahlidstaedu-vid-humira-i-haum-styrk 2026-04-29T13:29:22.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-expected-global-market-entry-dates-for-avt04-biosimilar-to-stelara-ustekinumab 2026-04-29T13:29:23.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tilkynnir-hvenaer-sala-a-avt04-liftaeknilyfjahlidstaedu-vid-stelara-getur-hafist-a-althjodlegum-morkudum 2026-04-29T13:29:23.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-positive-top-line-results-from-a-pharmacokinetic-study-for-avt03-a-proposed-biosimilar-for-prolia-and-xgeva 2026-04-29T14:19:16.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-kynnir-jakvaeda-nidurstodur-ur-rannsokn-a-lyfjahvorfum-avt03-fyrirhugadrar-liftaeknilyfjahlidstaedu-vid-prolia-og-xgeva 2026-04-29T14:19:16.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-6 2026-07-13T13:28:32.000Z 0.5 https://www.alvotech.com/is/newsroom/vidskipti-stjornenda-og-tengdra-adila-30 2026-07-13T13:28:32.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-provides-update-on-status-of-biologics-license-applications-for-avt02-and-avt04 2026-04-29T14:19:36.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-upplysingar-um-stodu-umsokna-um-markadsleyfi-fyrir-avt02-og-avt04-i-bandarikjunum 2026-04-29T14:19:36.000Z 0.5 https://www.alvotech.com/newsroom/stada-and-alvotech-secure-approval-for-uzpruvo-europe-s-first-ustekinumab-biosimilar-to-stelara 2026-04-29T14:20:01.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-stada-hljota-markadsleyfi-fyrir-fyrstu-liftaeknilyfjahlidstaeduna-vid-stelara-i-evropu 2026-04-29T14:20:01.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-clinical-study-results-demonstrate-therapeutic-equivalence-between-biosimilar-candidate-avt06-and-reference-product-eylea-aflibercept 2026-04-29T14:20:44.000Z 0.5 https://www.alvotech.com/is/newsroom/nidurstada-rannsoknar-a-sjuklingum-synir-somu-klinisku-virkni-avt06-liftaeknilyfjahlidstaedu-alvotech-og-eylea 2026-04-29T14:20:44.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-positive-top-line-results-from-a-pharmacokinetic-study-for-avt05-a-proposed-biosimilar-for-simponi-and-simponi-aria 2026-04-29T14:21:11.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-kynnir-jakvaedar-nidurstodur-ur-rannsokn-a-lyfjahvorfum-avt05-fyrirhugadri-liftaeknilyfjahlidstaedu-vid-simponi-og-simponi-aria 2026-04-29T14:21:11.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-reports-financial-results-for-first-nine-months-of-2023-and-provides-business-update 2026-04-29T13:29:25.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-uppgjor-fyrir-fyrstu-niu-manudi-arsins-2023-og-kynnir-helstu-afanga-a-lidnum-arsfjordungi 2026-04-29T13:29:25.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-report-financial-results-for-the-first-nine-months-of-2023-on-november-28-2023-and-host-business-update-conference-call-on-november-29-2023-at-8-00-am-et 2026-04-29T14:21:45.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-mun-birta-uppgjor-fyrstu-niu-manada-2023-thann-28-november-og-streyma-uppgjorsfundi-29-november-kl-13-00-ad-islenskum-tima 2026-04-29T14:21:45.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-accepts-offer-to-sell-its-subsidiary-in-hannover-germany 2026-07-09T13:05:49.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-jamp-pharma-announce-receipt-of-marketing-authorization-for-jamteki-avt04-the-first-biosimilar-of-stelara-ustekinumab 2026-04-29T13:29:26.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-jamp-pharma-hljota-markadsleyfi-i-kanada-fyrir-jamteki-liftaeknilyfjahlidstaedu-vid-stelara 2026-04-29T13:29:26.000Z 0.5 https://www.alvotech.com/newsroom/stada-and-alvotech-receive-positive-chmp-opinion-for-europe-s-first-ustekinumab-biosimilar-to-stelara 2026-04-29T14:20:16.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-stada-fyrst-til-ad-hljota-jakvaeda-afgreidslu-lyfjastofnunar-evropu-a-umsokn-um-markadsleyfi-fyrir-liftaeknilyfjahlidstaedu-vid-stelara 2026-04-29T14:20:16.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-present-at-the-jefferies-2023-london-healthcare-conference 2026-04-29T13:29:27.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tekur-thatt-i-heilbrigdisradstefnu-jefferies-i-london 2026-04-29T13:29:27.000Z 0.5 https://www.alvotech.com/newsroom/form-f-3-filed-with-the-united-states-securities-and-exchange-commission 2026-07-09T13:05:49.000Z 0.5 https://www.alvotech.com/is/newsroom/f-3-skraningareydublad-lagt-inn-til-verdbrefaeftirlits-bandarikjanna 2026-07-09T13:05:49.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-provides-update-on-status-of-u-s-biologics-license-application-for-avt04 2026-04-29T14:22:47.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-nyjar-upplysingar-um-stodu-umsoknar-um-markadsleyfi-fyrir-avt04-i-bandarikjunum 2026-04-29T14:22:47.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-islandsbanki-enter-into-market-making-agreement-for-shares-trading-on-nasdaq-iceland 2026-04-29T13:29:28.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-islandsbanki-gera-samning-um-vidskiptavakt-med-hlutabref-i-kauphollinni 2026-04-29T13:29:28.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-enters-into-exclusive-licensing-agreement-with-kashiv-biosciences-for-development-and-commercialization-of-a-proposed-biosimilar-to-xolair-omalizumab 2026-04-29T14:23:21.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-kashiv-biosciences-ganga-til-samstarfs-um-throun-og-markadssetningu-fyrirhugadrar-liftaeknilyfjahlidstaedu-vid-xolair-omalizumab 2026-04-29T14:23:21.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-approval-in-japan-of-avt04-ustekinumab-a-biosimilar-to-stelara 2026-04-29T14:23:45.000Z 0.5 https://www.alvotech.com/is/newsroom/markadsleyfi-veitt-i-japan-fyrir-avt04-ustekinumab-liftaeknilyfjahlidstaedu-alvotech-vid-stelara 2026-04-29T14:23:45.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-provides-u-s-regulatory-update-on-avt02-a-high-concentration-interchangeable-biosimilar-candidate-to-humira-adalimumab 2026-04-29T14:24:16.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-nyjar-upplysingar-um-stodu-umsoknar-um-markadsleyfi-fyrir-avt02-adalimumab-i-bandarikjunum 2026-04-29T14:24:16.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-participate-in-the-morgan-stanley-21st-annual-global-healthcare-conference 2026-04-29T13:29:30.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tekur-thatt-i-21-heilbrigdisradstefnu-morgans-stanleys 2026-04-29T13:29:30.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-changes-to-the-leadership-team 2026-04-29T14:24:38.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tilkynnir-um-breytingar-i-framkvaemdastjorn 2026-04-29T14:24:38.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-reports-financial-results-for-first-six-months-of-2023-and-provides-business-update 2026-04-29T13:29:31.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-uppgjor-fyrir-fyrri-helming-arsins-2023-og-kynnir-helstu-afanga-a-lidnum-arsfjordung 2026-04-29T13:29:31.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-bioventure-announce-approval-of-avt02-adalimumab-in-egypt 2026-04-29T14:24:59.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-bioventure-fa-markadsleyfi-fyrir-avt02-adalimumab-i-egyptalandi 2026-04-29T14:24:59.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-report-financial-results-for-the-first-half-of-2023-on-august-30-2023-and-host-business-update-conference-call-on-august-31-2023-at-8-00-am-et 2026-04-29T13:29:38.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-mun-birta-uppgjor-fyrri-arshelmings-2023-thann-30-agust-nk-og-streyma-uppgjorsfundi-31-agust-nk-kl-12-00-ad-islenskum-tima 2026-04-29T13:29:38.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-5 2026-06-15T20:09:17.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-completes-100-million-convertible-bond-private-placement 2026-04-29T14:25:32.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-lykur-lokudu-skuldabrefautbodi-ad-andvirdi-100-milljonir-dollara 2026-04-29T14:25:32.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-private-placement-of-convertible-bonds-to-qualified-investors-in-an-overseas-directed-offering 2026-07-09T13:05:49.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-selur-breytanleg-skuldabref-i-lokudu-utbodi 2026-07-09T13:05:49.000Z 0.5 https://www.alvotech.com/newsroom/teva-pharmaceuticals-and-alvotech-provide-update-on-strategic-biosimilars-partnership 2026-04-29T14:26:06.000Z 0.5 https://www.alvotech.com/is/newsroom/teva-og-alvotech-auka-vid-samstarf-sitt-um-throun-framleidslu-og-markadssetningu 2026-04-29T14:26:06.000Z 0.5 https://www.alvotech.com/newsroom/forms-filed-with-the-us-securities-and-exchange-commission-on-july-14-2023 2026-07-09T13:05:49.000Z 0.5 https://www.alvotech.com/newsroom/filing-of-previously-disclosed-partnership-agreements 2026-07-09T13:05:49.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-provides-regulatory-update-on-second-biologics-license-application-for-avt02 2026-04-29T14:26:27.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-upplysingar-um-stodu-umsoknar-um-markadsleyfi-i-bandarikjunum-fyrir-avt02 2026-04-29T14:26:27.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-4 2026-06-15T20:09:12.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-teva-secure-u-s-license-date-for-avt04-a-proposed-biosimilar-to-stelara 2026-04-29T14:26:55.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-teva-na-samningi-um-upphafsdag-solu-a-avt04-liftaeknilyfjahlidstaedu-vid-stelara-i-bandarikjunum 2026-04-29T14:26:55.000Z 0.5 https://www.alvotech.com/newsroom/main-results-of-annual-and-extraordinary-general-meeting-1 2026-07-09T13:05:44.000Z 0.5 https://www.alvotech.com/is/newsroom/nidurstada-adalfundar-1 2026-07-09T13:05:44.000Z 0.5 https://www.alvotech.com/newsroom/granting-of-stock-options 2026-07-09T13:05:43.000Z 0.5 https://www.alvotech.com/is/newsroom/uthlutun-kaupretta 2026-07-09T13:05:43.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-participate-in-jefferies-healthcare-conference 2026-04-29T13:29:41.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tekur-thatt-i-heilbrigdisradstefnu-fjarfestingabankans-jefferies 2026-04-29T13:29:41.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-3 2026-06-15T20:09:04.000Z 0.5 https://www.alvotech.com/newsroom/filing-of-information-related-to-press-release-on-agreement-between-alvotech-and-advanz-pharma 2026-07-09T13:05:48.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-advanz-pharma-extend-strategic-partnership-to-commercialize-five-proposed-biosimilars-in-europe 2026-04-29T14:27:16.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-advanz-pharma-auka-samstarfid-med-fyrirhugadri-markadssetningu-fimm-liftaeknilyfjahlidstaeda-i-evropu 2026-04-29T14:27:16.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-reports-financial-results-for-first-three-months-of-2023-and-provides-business-update 2026-04-29T14:27:38.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-uppgjor-fyrir-fyrstu-thrja-manudi-arsins-2023-og-kynnir-nyjustu-afanga-i-rekstri-felagsins 2026-04-29T14:27:38.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-participate-in-morgan-stanley-annual-sustainable-finance-summit 2026-04-29T13:29:42.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tekur-thatt-i-radstefnu-fjarfestingabankans-morgan-stanley-um-sjalfbaerar-fjarfestingar 2026-04-29T13:29:42.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-issues-annual-equality-report-covering-2022 2026-04-29T14:28:00.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-skyrslu-um-throun-jafnrettismala-a-arinu-2022 2026-04-29T14:28:00.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-enters-into-commercialization-agreement-with-polifarma-for-proposed-biosimilar-to-eylea-aflibercept 2026-04-29T13:29:43.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-semur-vid-polifarma-um-markadssetningu-fyrirhugadrar-liftaeknilyfjahlidstaedu-vid-eylea-aflibercept 2026-04-29T13:29:43.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-s-a-annual-general-meeting-to-be-held-june-6-2023 2026-04-29T13:29:44.000Z 0.5 https://www.alvotech.com/is/newsroom/adalfundur-alvotech-s-a-bodadur-6-juni-2023 2026-04-29T13:29:44.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-initiates-confirmatory-patient-study-for-avt05-a-proposed-biosimilar-for-simponi-and-simponi-aria 2026-04-29T13:29:44.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-hefur-kliniska-rannsokn-a-avt05-fyrirhugadri-liftaeknilyfjahlidstaedu-vid-simponi-og-simponi-aria 2026-04-29T13:29:44.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-report-first-quarter-2023-financial-results-and-recent-business-highlights-on-may-18-2023-and-host-conference-call-on-may-19-2023-at-8-00-am-et 2026-04-29T14:28:26.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-uppgjor-fyrsta-arsfjordungs-2023-thann-18-mai-nk-og-heldur-kynningarfund-19-mai-nk-kl-12-ad-islenskum-tima 2026-04-29T14:28:26.000Z 0.5 https://www.alvotech.com/newsroom/sarah-tanksley-joins-board-of-directors-for-alvotech-hf-and-sandra-casaca-appointed-chief-quality-officer 2026-04-29T13:30:05.000Z 0.5 https://www.alvotech.com/is/newsroom/sarah-tanksley-tekur-saeti-i-stjorn-alvotech-hf-og-sandra-casaca-skipud-framkvaemdastjori-gaedamala 2026-04-29T13:30:05.000Z 0.5 https://www.alvotech.com/newsroom/fda-status-update 2026-07-09T13:05:48.000Z 0.5 https://www.alvotech.com/is/newsroom/uppfaerdar-upplysingar-fra-matvaela-og-lyfjaeftirliti-bandarikjanna-fda 2026-07-09T13:05:48.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-provides-regulatory-update-on-avt02-biologics-license-application 2026-04-29T13:30:06.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-nyjar-upplysingar-um-stodu-umsoknar-um-markadsleyfi-i-bandarikjunum-fyrir-avt02 2026-04-29T13:30:06.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-19 2026-06-15T20:11:33.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-increase-in-number-of-own-shares-23 2026-07-09T13:05:43.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tilkynnir-um-utgafu-eigin-hlutabrefa-1 2026-07-09T13:05:43.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-provides-update-on-corporate-sustainability-framework 2026-04-29T14:28:52.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-nyjar-upplysingar-um-sjalfbaerni-og-samfelagslega-abyrgd 2026-04-29T14:28:52.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-present-clinical-study-data-for-avt04-a-proposed-biosimilar-to-stelara-at-2023-american-academy-of-dermatology-aad-annual-meeting 2026-04-29T14:29:13.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-kynnir-nidurstodur-kliniskra-rannsokna-a-avt04-fyrirhugadri-hlidstaedu-vid-stelara-a-arsthingi-samtaka-bandariskra-hudsjukdomalaekna-aad 2026-04-29T14:29:13.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-reports-financial-results-for-full-year-2022-and-provides-business-update 2026-04-29T13:30:07.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-uppgjor-fyrir-arid-2022-og-kynnir-nyjustu-afanga-i-rekstri-felagsins 2026-04-29T13:30:07.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-webcast-of-2022-full-year-financial-results-at-8-00-am-et-on-march-2-2023 2026-04-29T13:30:07.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-uppgjor-arsins-2022-thann-1-mars-nk-og-heldur-kynningarfund-2-mars-nk 2026-04-29T13:30:07.000Z 0.5 https://www.alvotech.com/newsroom/updated-market-making-agreement-with-landsbankinn-for-alvotech-shares-trading-on-the-nasdaq-iceland-market 2026-04-29T13:30:08.000Z 0.5 https://www.alvotech.com/is/newsroom/uppfaerdur-samningur-vid-landsbankann-um-vidskiptavakt-a-hlutabrefum-alvotech-a-nasdaq-iceland-markadnum 2026-04-29T13:30:08.000Z 0.5 https://www.alvotech.com/newsroom/settlement-of-alvotech-private-share-placement-completed 2026-04-29T14:29:38.000Z 0.5 https://www.alvotech.com/is/newsroom/uppgjori-vidskipta-i-lokudu-hlutafjarutbodi-lokid 2026-04-29T14:29:38.000Z 0.5 https://www.alvotech.com/newsroom/ema-confirms-acceptance-of-application-for-avt04-a-proposed-biosimilar-to-stelara-ustekinumab 2026-04-29T14:29:56.000Z 0.5 https://www.alvotech.com/is/newsroom/evropska-lyfjastofnunin-samthykkir-ad-taka-fyrir-leyfisumsokn-fyrir-fyrirhugada-hlidstaedu-vid-stelara-ustekinumab 2026-04-29T14:29:56.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-enters-into-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-xolair-omalizumab 2026-04-29T13:30:09.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-semur-vid-advanz-pharma-um-markadssetningu-liftaeknilyfjahlidstaedu-vid-xolair-omalizumab 2026-04-29T13:30:09.000Z 0.5 https://www.alvotech.com/is/newsroom/birting-skraningarskjals-vegna-breytilegra-skuldabrefa-alvcvb251220 2026-07-09T13:05:43.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-bioventure-announce-approval-of-avt02-adalimumab-as-simlandi-in-saudi-arabia 2026-04-29T13:30:09.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-bioventure-fa-markadsleyfi-fyrir-avt02-adalimumab-i-sadi-arabiu 2026-04-29T13:30:09.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-completes-137-million-private-share-placement 2026-04-29T14:30:15.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-selur-hlutabref-fyrir-19-5-milljarda-krona-i-lokudu-utbodi-til-innlendra-fagfjarfesta 2026-04-29T14:30:15.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-initiates-proposed-private-share-placement-to-professional-clients-and-eligible-counterparties-in-iceland 2026-07-09T13:05:48.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-hefur-ferli-vid-solu-almennra-hlutabrefa-i-lokud-utbodi-til-fagfjarfesta-og-vidurkenndra-gagnadila 2026-07-09T13:05:48.000Z 0.5 https://www.alvotech.com/newsroom/fda-inspection-of-manufacturing-facility 2026-07-09T13:05:48.000Z 0.5 https://www.alvotech.com/is/newsroom/uttekt-bandariska-lyfjaeftirlitsins-a-framleidsluadstodu 2026-07-09T13:05:48.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-fuji-pharma-expand-partnership-adding-a-new-biosimilar-candidate 2026-04-29T13:30:18.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-fuji-pharma-baeta-fyrirhugadri-liftaeknilyfjahlidstaedu-vid-samstarf-sitt-a-japansmarkadi 2026-04-29T13:30:18.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-initiates-pharmacokinetic-study-for-avt05-a-proposed-biosimilar-for-simponi-and-simponi-aria 2026-04-29T14:30:48.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-hefur-rannsokn-a-lyfjahvorfum-avt05-fyrirhugadri-liftaeknilyfjahlidstaedu-vid-simponi-og-simponi-aria 2026-04-29T14:30:48.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-teva-announce-acceptance-of-u-s-biologics-license-application-for-avt04-a-proposed-biosimilar-to-stelara-ustekinumab 2026-04-29T13:30:19.000Z 0.5 https://www.alvotech.com/is/newsroom/bandariska-lyfjaeftirlitid-samthykkir-ad-taka-fyrir-umsokn-um-markadsleyfi-fyrir-avt04-fyrirhugada-liftaeknilyfjahlidstaedu-alvotech-vid-stelara 2026-04-29T13:30:19.000Z 0.5 https://www.alvotech.com/newsroom/update-on-u-s-regulatory-status-of-avt02-alvotech-s-proposed-high-concentration-interchangeable-biosimilar-to-humira 2026-04-29T14:31:19.000Z 0.5 https://www.alvotech.com/is/newsroom/stada-umsokna-alvotech-um-markadsleyfi-i-bandarikjunum-fyrir-avt02-utskiptilega-liftaeknilyfjahlidstaedu-vid-humira 2026-04-29T14:31:19.000Z 0.5 https://www.alvotech.com/newsroom/correction-to-total-amount-in-announcement-about-private-placement-published-2022-12-16-09-00-gmt 2026-04-29T13:30:20.000Z 0.5 https://www.alvotech.com/is/newsroom/leidretting-a-heildarfjarhaed-i-tilkynningu-um-skuldabrefafjarmognun-birt-2022-12-16-09-00-gmt 2026-04-29T13:30:20.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-completes-59-7-million-private-placement 2026-04-29T13:30:21.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-gengur-fra-um-8-5-milljarda-krona-skuldabrefafjarmognun 2026-04-29T13:30:21.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-shares-start-trading-on-nasdaq-iceland-main-market 2026-04-29T14:31:53.000Z 0.5 https://www.alvotech.com/is/newsroom/hlutabref-alvotech-tekin-til-vidskipta-a-adalmarkadi-nasdaq-a-islandi 2026-04-29T14:31:53.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-stada-broaden-access-to-hukyndra-adalimumab-biosimilar-in-europe 2026-04-29T14:32:17.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-stada-auka-adgengi-sjuklinga-ad-hukyndra-adalimumab-i-evropu 2026-04-29T14:32:17.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-publishes-prospectus-related-to-the-admission-to-trading-and-listing-on-nasdaq-iceland-main-market 2026-07-09T13:05:47.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-skraningarlysingu-i-tengslum-vid-flutning-a-adalmarkad-nasdaq-iceland 2026-07-09T13:05:47.000Z 0.5 https://www.alvotech.com/newsroom/nasdaq-iceland-approves-the-request-for-trading-of-alvotech-s-shares-on-the-main-market 2026-04-29T13:30:22.000Z 0.5 https://www.alvotech.com/is/newsroom/nasdaq-iceland-samthykkir-beidni-um-ad-taka-hlutabref-alvotech-til-vidskipta-a-adalmarkadnum 2026-04-29T13:30:22.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-restricted-share-unit-agreements 2026-07-09T13:05:47.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-changes-to-its-leadership-team 2026-04-29T13:30:22.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-gerir-breytingar-a-yfirstjorn-fyrirtaekisins 2026-04-29T13:30:22.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-submits-its-application-for-admission-of-the-company-s-shares-to-trading-on-nasdaq-iceland-main-market 2026-04-29T13:30:23.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-leggur-inn-umsokn-um-toku-hlutabrefa-til-vidskipta-a-adalmarkadi-nasdaq-iceland 2026-04-29T13:30:23.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-secures-financing-facilities-of-approximately-136-million 2026-04-29T13:30:23.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tryggir-adgengi-ad-um-20-milljarda-krona-fjarmognun 2026-04-29T13:30:23.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-reports-financial-results-for-first-nine-months-of-2022-and-provides-business-update 2026-04-29T13:30:24.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-kynnir-uppgjor-fyrir-fyrstu-niu-manudi-arsins-2022-og-skyrir-fra-helstu-afongum-i-rekstri 2026-04-29T13:30:24.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-australian-marketing-authorization-for-avt02-a-biosimilar-to-humira 2026-04-29T13:30:24.000Z 0.5 https://www.alvotech.com/is/newsroom/markadsleyfi-veitt-fyrir-avt02-liftaeknilyfjahlidstaedu-alvotech-vid-humira-i-astraliu 2026-04-29T13:30:24.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-present-switching-study-data-for-avt02-a-proposed-biosimilar-to-humira-at-2022-american-college-of-rheumatology-conference 2026-04-29T13:30:24.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-rannsokn-a-utskiptileika-avt02-liftaeknilyfjahlidstaedu-vid-humira-a-radstefnu-bandarisku-gigtarlaeknasamtakanna 2026-04-29T13:30:24.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-report-first-nine-months-financial-results-on-november-15-2022-and-host-business-update-conference-call-at-8-00-am-et-on-november-16-2022 2026-04-29T13:30:25.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-mun-birta-uppgjor-fyrir-fyrstu-niu-manudi-arsins-2022-thann-15-november-og-heldur-kynningarfund-16-november 2026-04-29T13:30:25.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-participate-in-upcoming-jefferies-london-healthcare-conference-in-november 2026-04-29T14:32:40.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tekur-thatt-i-heilbrigdisradstefnu-jefferies-i-london-i-november-2022 2026-04-29T14:32:40.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-jamp-pharma-expand-exclusive-partnership-adding-two-biosimilar-candidates-for-canadian-market-bringing-new-options-for-patients-in-specialty-care 2026-04-29T13:30:25.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-jamp-pharma-fjolga-samstarfsverkefnum-til-ad-baeta-adgengi-ad-liftaeknilyfjum-i-kanada 2026-04-29T13:30:25.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-s-partner-submits-application-for-marketing-approval-of-first-biosimilar-candidate-in-japan 2026-04-29T14:33:05.000Z 0.5 https://www.alvotech.com/is/newsroom/samstarfsadili-alvotech-saekir-um-markadsleyfi-fyrir-fyrstu-liftaeknilyfjahlidstaeduna-i-japan 2026-04-29T14:33:05.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-appoints-sarah-tanksley-as-chief-quality-officer 2026-04-29T13:30:26.000Z 0.5 https://www.alvotech.com/is/newsroom/sarah-tanksley-radin-framkvaemdastjori-gaedaeftirlits-hja-alvotech 2026-04-29T13:30:26.000Z 0.5 https://www.alvotech.com/newsroom/attached-is-an-announcement-on-transactions-of-managers-and-closely 2026-05-27T15:19:58.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-stada-increase-access-to-adalimumab-for-patients-in-switzerland-with-the-launch-of-hukyndra 2026-04-29T13:30:27.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-og-stada-hefja-solu-a-hukyndra-i-sviss-og-auka-adgengi-sjuklinga-ad-adalimumab 2026-04-29T13:30:27.000Z 0.5 https://www.alvotech.com/newsroom/filing-of-amendment-no-1-to-preliminary-prospectus-on-form-f-1-with-u-s-securities-and-exchange-commission 2026-07-09T13:05:47.000Z 0.5 https://www.alvotech.com/newsroom/filing-of-amendment-no-2-to-preliminary-prospectus-on-form-f-1-with-u-s-securities-and-exchange-commission 2026-07-09T13:05:47.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-reports-update-on-initial-avt02-biologics-license-application 2026-04-29T14:33:31.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-birtir-nyjar-upplysingar-um-stodu-upprunalegu-leyfisumsoknarinnar-fyrir-avt02-i-bandarikjunum 2026-04-29T14:33:31.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-reports-first-half-2022-financial-results-and-business-update 2026-04-29T14:33:57.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-kynnir-uppgjor-fyrir-fyrstu-sex-manudi-arsins-2022-og-skyrir-fra-helstu-afongum-fra-aramotum 2026-04-29T14:33:57.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-corporate-sustainability-participation-and-discloses-esg-data-covering-2020-and-2021 2026-04-29T13:30:28.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-leggur-aherslu-a-sjalfbaerni-og-samfelagslega-abyrgd-og-birtir-upplysingar-fyrir-arin-2020-og-2021 2026-04-29T13:30:28.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-initiates-confirmatory-patient-study-for-avt03-a-proposed-biosimilar-for-prolia-and-xgeva 2026-04-29T14:34:21.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-hefur-kliniska-rannsokn-a-avt03-fyrirhugadri-liftaeknilyfjahlidstaedu-vid-prolia-og-xgeva 2026-04-29T14:34:21.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-participate-in-two-upcoming-investor-conferences-in-september-2022 2026-04-29T14:34:37.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-tekur-thatt-i-tveimur-althjodlegum-fjarfestaradstefnum-i-september-2022 2026-04-29T14:34:37.000Z 0.5 https://www.alvotech.com/newsroom/filing-of-registration-statement-on-form-s-8-with-the-u-s-securities-and-exchange-commission 2026-07-09T13:05:47.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-to-report-first-six-months-and-second-quarter-2022-financial-results-on-august-31-2022-and-host-business-update-conference-call-at-8-00-am-et-on-september-1-2022 2026-04-29T14:34:54.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-mun-birta-uppgjor-fyrir-fyrsta-arshelming-og-annan-arsfjordung-2022-thann-31-agust-og-heldur-kynningarfund-1-september 2026-04-29T14:34:54.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-s-board-of-directors-approves-plan-to-prepare-for-listing-on-nasdaq-main-market-in-iceland 2026-04-29T14:35:15.000Z 0.5 https://www.alvotech.com/is/newsroom/stjorn-alvotech-samthykkir-aaetlun-um-ad-undirbua-skraningu-a-adalmarkad-nasdaq-a-islandi 2026-04-29T14:35:15.000Z 0.5 https://www.alvotech.com/newsroom/filing-of-amendment-to-preliminary-prospectus-on-form-f-1-with-u-s-securities-and-exchange-commission 2026-07-09T13:05:47.000Z 0.5 https://www.alvotech.com/newsroom/filing-of-preliminary-prospectus-on-form-f-1-with-u-s-securities-and-exchange-commission 2026-07-09T13:05:46.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-initiates-a-pharmacokinetic-study-for-avt03-a-proposed-biosimilar-for-prolia-and-xgeva 2026-04-29T14:35:49.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-hefur-rannsokn-a-lyfjahvorfum-avt03-fyrirhugadri-liftaeknilyfjahlidstaedu-vid-prolia-og-xgeva 2026-04-29T14:35:49.000Z 0.5 https://www.alvotech.com/newsroom/filing-of-preliminary-prospectus-on-form-f-1-with-u-s-securities-and-exchange-commission-1 2026-07-09T13:05:46.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-expands-its-board-of-directors-as-part-of-transition-from-private-to-publicly-traded-company 2026-04-29T13:30:39.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-fjolgar-stjornarmonnum-vid-skraningu-a-markad 2026-04-29T13:30:39.000Z 0.5 https://www.alvotech.com/newsroom/transactions-of-managers-and-closely-associated-persons-2 2026-06-15T20:08:59.000Z 0.5 https://www.alvotech.com/newsroom/aztiq-and-alvogen-subscribe-to-shares-in-alvotech-at-listing-price-of-10-per-share 2026-07-09T13:05:46.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-initiates-patient-study-for-avt06-a-proposed-biosimilar-for-eylea 2026-04-29T14:36:15.000Z 0.5 https://www.alvotech.com/is/newsroom/alvotech-hefur-kliniska-rannsokn-a-avt06-fyrirhugadri-liftaeknilyfjahlidstaedu-vid-eylea 2026-04-29T14:36:15.000Z 0.5 https://www.alvotech.com/newsroom/increase-of-share-capital-and-creation-of-treasury-share-pool-to-meet-obligations-with-respect-to-warrants-issued-by-alvotech-the-management-incentive-plan-as-well-as-option-to-iss 2026-07-09T09:55:35.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-debuts-nasdaq-first-north-growth-market-becoming-first 2026-04-29T14:36:36.000Z 0.5 https://www.alvotech.com/newsroom/supplement-company-description 2026-07-13T13:28:33.000Z 0.5 https://www.alvotech.com/is/newsroom/vidauki-vid-skraningarskjal-1 2026-07-13T13:28:33.000Z 0.5 https://www.alvotech.com/newsroom/supplement-to-the-company-description 2026-04-29T13:30:40.000Z 0.5 https://www.alvotech.com/is/newsroom/vidauki-vid-skraningarskjal 2026-04-29T13:30:40.000Z 0.5 https://www.alvotech.com/newsroom/publication-of-a-company-description-and-intended-listing-on-first-north-iceland 2026-07-09T09:55:36.000Z 0.5 https://www.alvotech.com/is/newsroom/birting-skraningarskjals-vegna-fyrirhugadrar-skraningar-a-first-north-iceland 2026-07-09T09:55:36.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-global-pureplay-biosimilars-company-debut-nasdaq-under 2026-04-29T13:45:18.000Z 0.5 https://www.alvotech.com/newsroom/stada-and-alvotech-broaden-european-patients-options-launching 2026-05-08T16:02:16.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-oaktree-acquisition-corpii-announce-shareholder 2026-05-08T16:02:02.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-clinical-study-results-demonstrate-therapeutic 2026-05-08T16:01:06.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-positive-results-pharmacokinetic-similarity 2026-05-08T16:00:58.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-oacb-announce-extraordinary-general-meeting-approve 2026-05-08T16:00:51.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-improves-access-capital-and-streamlines-path-expected 2026-05-08T15:59:55.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-stada-pave-way-launching-hukyndraravt02-citrate 2026-05-08T15:59:49.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-resolves-us-patent-and-trade-secret-disputes-abbvie 2026-05-08T15:59:33.000Z 0.5 https://www.alvotech.com/newsroom/fda-accepts-alvotechs-bla-supporting-interchangeability-atv02 2026-05-08T15:59:42.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-fuji-pharma-expand-partnership-additional 2026-05-08T15:59:18.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-enters-exclusive-global-licensing-agreement 2026-05-08T15:59:12.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-upsizes-oversubscribed-pipe-transaction-approximately 2026-05-08T15:59:05.000Z 0.5 https://www.alvotech.com/newsroom/jamp-and-alvotech-announce-canadian-approval-simlanditm-high 2026-05-08T15:58:57.000Z 0.5 https://www.alvotech.com/newsroom/avt02-approved-use-european-union 2026-05-08T15:58:50.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-oaktree-acquisition-corp-ii-announce-merger 2026-05-08T15:58:42.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-beats-back-abbvies-trade-secrets-lawsuit 2026-05-08T15:58:35.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-provides-update-fda-action-regarding-avt02-proposed 2026-05-08T15:58:27.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-welcomes-positive-chmp-opinion-avt02-proposed 2026-05-08T15:58:20.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-positive-top-line-results-switching-study 2026-05-08T15:58:03.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-bondholders-convert-more-100m-pre-money-valuation-27bn 2026-05-08T15:58:13.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-reaches-primary-completion-date-its-switching-study 2026-05-08T15:57:56.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-seeks-end-abbvies-wrongful-monopoly-humira-and-bring 2026-05-08T15:57:49.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-disputes-abbvies-allegations-wrongdoing 2026-05-08T15:57:42.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-completes-second-round-us-100m-private-placement 2026-05-08T15:57:34.000Z 0.5 https://www.alvotech.com/newsroom/cipla-gulf-and-alvotech-expand-partnership-commercialization 2026-05-08T15:57:28.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-fuji-pharma-extend-biosimilar-partnership-japan 2026-05-08T15:57:21.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-ccht-biopharmaceutical-and-yangtze-river-pharmaceutical 2026-05-08T15:57:14.000Z 0.5 https://www.alvotech.com/newsroom/us-fda-and-ema-have-accepted-regulatory-submissions-avt02 2026-05-08T15:57:06.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-cipla-partner-ensure-access-biosimilars-south 2026-05-08T15:56:58.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-private-placement-financing 2026-05-08T15:56:52.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-dksh-extend-partnership-asia 2026-05-08T15:56:46.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-teva-announce-strategic-partnership-collaborate-us 2026-05-08T15:56:40.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-announces-positive-top-line-results-two-comparative 2026-05-08T15:56:33.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-dksh-partner-bring-key-biosimilar-asia 2026-05-08T15:56:26.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-jamp-pharma-enter-exclusive-partnership 2026-05-08T15:56:18.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-stada-agree-strategic-biosimilar-partnership 2026-05-08T15:56:10.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-cipla-gulf-partnership 2026-05-08T15:56:00.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-completes-enrollment-phase-iii-study-involving 2026-05-08T15:55:53.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-abdi-ibrahim-enter-exclusive-partnership 2026-05-08T15:55:47.000Z 0.5 https://www.alvotech.com/newsroom/mark-levick-appointed-ceo-alvotech 2026-05-08T15:55:39.000Z 0.5 https://www.alvotech.com/newsroom/yas-holding-invests-alvotech-and-agrees-strategic-partnership 2026-05-08T15:55:31.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-fuji-pharma-announce-agreement 2026-05-08T15:55:23.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-enrolls-first-patient-clinical-phase-iii-study 2026-05-08T15:55:16.000Z 0.5 https://www.alvotech.com/newsroom/work-begins-alvotech-cchn-joint-venture-china 2026-05-08T15:55:09.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-completes-us-300m-financing-deal 2026-05-08T15:55:02.000Z 0.5 https://www.alvotech.com/newsroom/fuji-pharma-invests-alvotech-us50-million 2026-05-08T15:54:51.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-fuji-pharma-enter-exclusive-agreement 2026-05-08T15:54:41.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-and-changchun-high-new-technology-industries-enter 2026-05-08T15:54:34.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-receives-manufacturing-license-its-biopharmaceutical 2026-05-08T15:54:26.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-opens-state-art-biosimilar-facility-iceland 2026-05-08T15:54:18.000Z 0.5 https://www.alvotech.com/newsroom/alvotech-completes-acquisition-baliopharm 2026-05-08T15:54:09.000Z 0.5